Thursday, April 07, 2016 9:32:19 AM
"The company has received notification from the US Food and Drug Administration to proceed with combination Phase I/ II clinical trial for OXS-1550"
"Oxis' lead drug candidate, OXS-1550, is in Phase 1/Phase 2 clinical trial at the University of Minnesota Masonic Cancer Center as a treatment for non-Hodgkins lymphoma and leukemia.
"TAMPA, Fla., Nov. 23, 2015 /PRNewswire/ -- Oxis Biotech, Inc. (OXIS), a wholly owned subsidiary of Oxis International, Inc. [OTC: OXIS] and [Euronext Paris: OXI.PA] announced today its collaborators at the University of Minnesota Masonic Cancer Center received notification from the U.S. Food and Drug Administration (FDA) that they can proceed with their planned combination Phase 1/Phase 2 clinical trial for OXS-1550. Oxis holds worldwide exclusive rights to develop and commercialize OXS-1550, a novel therapy for the treatment of leukemia and lymphoma.
Recent GTBP News
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 06/13/2024 08:14:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/07/2024 09:25:06 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 05/24/2024 12:31:08 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/23/2024 10:04:59 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 10:02:41 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 09:00:40 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 07:46:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 05:15:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/21/2023 08:30:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/04/2023 10:00:11 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 11/06/2023 10:25:12 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 11/06/2023 10:23:32 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/06/2023 10:21:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/01/2023 01:00:37 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 10/27/2023 09:23:48 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 09/19/2023 03:56:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/22/2023 08:55:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/15/2023 11:29:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/15/2023 11:26:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/07/2023 01:30:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/05/2023 01:00:11 PM
FEATURED Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • Jun 14, 2024 2:07 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM
Element79 Gold Corp Files for OTCQB Uplisting, Provides Financial Update • ELEM • Jun 11, 2024 9:25 AM